Original article posted on Healio
Dry eye disease (DED) is a condition of the ocular surface in which multiple factors are responsible for the disturbance of the stability of tear film, leading to changes in vision and symptoms that significantly disrupt the quality of life of many individuals in the United States and elsewhere.
There is a well-known association of several systemic diseases with DED – among them includes Sjögren’s syndrome, rheumatoid arthritis, scleroderma, and systemic lupus erythematosus.
Cyclosporine has been the prototype anti-inflammatory selective drug used to treat DED and was the first drug approved by the US Food and Drug Administration (FDA) to improve the production of tears in patients with DED. Most recently, Lifitegrast ophthalmic solution 5% was the first drug approved by the FDA for the treatment of signs and symptoms of patients with DED.
For more information about dry eye disease, please contact us at North Toronto Eye Care today.